Chills

Mouser Electronics Empowers Next Generation of Engineers as Registration Sponsor of FIRST Robotics Championship

Retrieved on: 
Lunedì, Aprile 15, 2024
Semiconductor, Manufacturing, Other Science, Other Technology, Hardware, Electronic Design Automation, Foundation, Philanthropy, Science, Consumer Electronics, Technology, Robotics, Other Manufacturing, Other Education, Machinery, Primary, Secondary, Engineering, Training, Education, FIRST Robotics Competition, News, Character, Sport, Marketing, Chills, STEM, Robot, Senior, Electronics, FIRST, NPI, Multimedia

Mouser will be the registration sponsor at the upcoming FIRST Championships, April 17-20, at the George R. Brown Convention Center in Houston, Texas.

Key Points: 
  • Mouser will be the registration sponsor at the upcoming FIRST Championships, April 17-20, at the George R. Brown Convention Center in Houston, Texas.
  • Mouser supports FIRST teams in its local community, providing grants for high school teams across Tarrant County, Texas.
  • View the full release here: https://www.businesswire.com/news/home/20240415197730/en/
    Mouser will be the registration sponsor at the upcoming FIRST Championships, April 17-20, at the George R. Brown Convention Center in Houston, Texas.
  • "As an avid supporter of the FIRST Robotics Competition since 2014, we are excited to be named this year's registration sponsor.

Menopause Impacts More Than Half the Workforce, but Menopausal Support in the Workplace Is Critically Lacking: New Insights From McLean & Company

Retrieved on: 
Mercoledì, Aprile 24, 2024
DEI, Education, Brain, Menopause, Learning, Woman, Intersex, SHRM, Emotional intelligence, Traction, Communication, Workplace, Morale, Research, Insomnia, Depression, Environment, Taboo, Privacy, Irritability, Interface (computing), Workforce, Chills, Empathy, Confidentiality, Anxiety, Organization, Knowledge, Management

"We know that menopause affects women, individuals with medical menopause related to personal health needs, as well as some non-binary, intersex, and transgender people.

Key Points: 
  • "We know that menopause affects women, individuals with medical menopause related to personal health needs, as well as some non-binary, intersex, and transgender people.
  • This means approximately half of the workforce is impacted by menopause," says Karen Mann , senior vice president, Human Resources Research, Learning & Advisory Services at McLean & Company.
  • "While there is often more support for menopause in the workplace in regions such as Northern Europe, New Zealand, and Australia, menopausal support is critically lacking in North American environments.
  • These challenges can span multiple years across four phases, which are pre-menopause, perimenopause, menopause, and post-menopause, and can be managed through tailored workplace support.

Dynabook E11 Series Windows 11 Pro Laptops and 2-in-1s for K-12 Education Now Shipping

Retrieved on: 
Mercoledì, Aprile 17, 2024
E11, Education, Windows Ink, LAN, System, Learning, Somatosensory system, IPS, Chills, Wi-Fi, Student, Windows 11, HD, Tablet, USB, K-12

IRVINE, Calif., April 17, 2024 /PRNewswire/ -- Dynabook Americas, Inc., the gold standard for long-lasting, professional-grade laptops, today announces that its new Windows 11 Pro equipped E11 Series laptops and 2-in-1 convertibles designed for K-12 education are now shipping. Following a successful pre-order phase, these innovative classroom multitools are now en route to empower student learning for the 2024-2025 school year.

Key Points: 
  • With Windows 11 Pro Education, Dynabook E11 Series Laptops Empower Students with State-of-the-Art Tools, Optimize Classroom Performance and Facilitate a Smooth Transition into Their Careers
    IRVINE, Calif., April 17, 2024 /PRNewswire/ -- Dynabook Americas, Inc. , the gold standard for long-lasting, professional-grade laptops, today announces that its new Windows 11 Pro equipped E11 Series laptops and 2-in-1 convertibles designed for K-12 education are now shipping.
  • Designed to elevate hybrid learning and equipped with advanced features, the Dynabook E11 Series represents a significant advancement in 1-in-1 computing for education.
  • Equipping our E11 series laptops with Windows 11 Pro Education offers numerous advantages to both students, educators, and school IT staff," continued Robbins.
  • To learn more about the new E11 education laptops from Dynabook, please contact your authorized Dynabook dealer, or visit us.dynabook.com .

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
Venerdì, Aprile 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

Dr. Goodyear, Integrative Cancer Expert, Observes Benefits When Using CBD IV Therapy by Pico IV with Oncology Patients

Retrieved on: 
Mercoledì, Aprile 10, 2024
Pain, Brain, Jarisch–Herxheimer reaction, Blood pressure, Nausea, Diabetes, Bone metastasis, Embolism, Depression, Seizure, Obesity, Blood, Patient, Liver, Headache, Hypertension, Chills, Infection, Cannabidiol, Thrombosis, Fever, Anxiety, Medical device

SCOTTSDALE, Ariz., April 10, 2024 /PRNewswire/ -- Medical director of an integrative oncology center in Scottsdale, AZ, Nathan Goodyear, MD, MD(H), began using CBD IV Therapy by Pico IV over four months ago with cancer patients under his care.

Key Points: 
  • SCOTTSDALE, Ariz., April 10, 2024 /PRNewswire/ -- Medical director of an integrative oncology center in Scottsdale, AZ, Nathan Goodyear, MD, MD(H), began using CBD IV Therapy by Pico IV over four months ago with cancer patients under his care.
  • He found that CBD IV therapy was well-tolerated by almost all patients, with only two experiencing a Jarisch-Herxheimer reaction due to undiagnosed port infections.
  • Pico IV are the makers of the world's first CBD IV therapy.
  • Joe Young, CEO of Pico IV Inc, shared "When we first launched CBD IV Therapy, we were excited about the potential benefits for users.

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Martedì, Marzo 26, 2024
COVID-19 vaccine, Risk, Headache, COVID-19, Ageing, Public, Vaccine, MRNA, Messenger, Chills, SARS-CoV-2, Myalgia, Clinical trial, Safety, Omicron, Fatigue

"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • "We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stephane Bancel, Chief Executive Officer of Moderna.
  • "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
  • In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222.
  • A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.

ValleyScare is Back from the Dead!

Retrieved on: 
Martedì, Aprile 2, 2024
Halloween, Valleyfair, Policy, Sale, Moon, Chills, Amusement park

For those looking for a more family-friendly experience, Tricks and Treats is also returning with day-time Halloween fun this fall.

Key Points: 
  • For those looking for a more family-friendly experience, Tricks and Treats is also returning with day-time Halloween fun this fall.
  • Key features of ValleyScare include:
    ValleyScare will be operating select Fridays and Saturdays, September 21 through October 26, 2024.
  • In a change from previous years, ValleyScare will be a stand-alone event requiring a separate ticket.
  • We can’t wait for you to eagerly plunge into all the frighteningly fun, thrill-filled festivities.”
    For more information about ValleyScare, please visit valleyfair.com.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Martedì, Marzo 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Martedì, Marzo 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Sabato, Aprile 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.